Rchr
J-GLOBAL ID：202301006964586299
Update date: May. 06, 2024
Shitara Kohei
シタラ コウヘイ | Shitara Kohei
Affiliation and department：
Research theme for competitive and other funds (2)：
- 2022 - 2025 Elucidation of regulation mechanisms of immune surveillance and tolerance by spatial multi-scale analysis of cancer
- 2017 - 2022 New Classification of triple negative breast cancer (TNBC) based on immune status with clinical characteristic
Papers (78)：
-
Kohei Shitara, Kei Muro, Jun Watanabe, Kentaro Yamazaki, Hisatsugu Ohori, Manabu Shiozawa, Atsuo Takashima, Mitsuru Yokota, Akitaka Makiyama, Naoya Akazawa, et al. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer. Nature medicine. 2024. 30. 3. 730-739
-
Tadayoshi Hashimoto, Yoshiaki Nakamura, Saori Mishima, Izuma Nakayama, Daisuke Kotani, Akihito Kawazoe, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Naoko Iida, et al. Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential. Cancer science. 2024
-
Shogo Takei, Yosuke Tanaka, Yi-Tzu Lin, Shohei Koyama, Shota Fukuoka, Hiroki Hara, Yoshiaki Nakamura, Yasutoshi Kuboki, Daisuke Kotani, Takashi Kojima, et al. Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer. Journal for immunotherapy of cancer. 2024. 12. 2
-
Kohei Shitara, Sun Young Rha, Lucjan S Wyrwicz, Takashi Oshima, Nina Karaseva, Mikhail Osipov, Hisateru Yasui, Hiroshi Yabusaki, Sergey Afanasyev, Young-Kyu Park, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. The Lancet. Oncology. 2023
-
Kohei Shitara, Kensei Yamaguchi, Kei Muro, Hisateru Yasui, Daisuke Sakai, Takashi Oshima, Masahiro Fujimura, Yuta Sato, Shunsuke Yamazaki, Tatsuya Wakabayashi, et al. Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study. International journal of clinical oncology. 2023
ｍore...
MISC (15)：
-
Takayuki Yoshino, Jun Watanabe, Kohei Shitara, Hirofumi Yasui, Hisatsugu Ohori, Manabu Shiozawa, Kentaro Yamazaki, Eiji Oki, Takeo Sato, Takeshi Naitoh, et al. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial. JOURNAL OF CLINICAL ONCOLOGY. 2022. 40. 17
-
Satoshi Yuki, Yoshiaki Nakamura, Hiroya Taniguchi, Tadamichi Denda, Tomohiro Nishina, Yasuo Hamamoto, Hiroki Hara, Taito Esaki, Hisato Kawakami, Atsuo Takashima, et al. Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC. JOURNAL OF CLINICAL ONCOLOGY. 2021. 39. 3
-
Tomohiro Kadota, Daisuke Kotani, Yusuke Yoda, Miki Fukutani, Masashi Wakabayashi, Shogo Nomura, Nozomu Fuse, Akihiro Sato, Tomonori Yano, Kohei Shitara. A phase Ib study of near infrared photoimmunotherapy (NIR-PIT) using ASP-1929 in combination with nivolumab and for patients with advanced gastric or esophageal cancer (GE-PIT study, EPOC1901). JOURNAL OF CLINICAL ONCOLOGY. 2020. 38. 4
-
Akihito Kawazoe, Shota Fukuoka, Yoshiaki Nakamura, Yasutoshi Kuboki, Yuichi Mikamoto, Hikari Shima, Noriko Fujishiro, Tsukiko Higuchi, Masashi Wakabayashi, Shogo Nomura, et al. An open-label phase II study of lenvatinib plus pembrolizumab in patients with advanced gastric cancer (EPOC1706). JOURNAL OF CLINICAL ONCOLOGY. 2020. 38. 4
-
Kohei Shitara, Hiroki Hara, Naoki Takahashi, Takashi Kojima, Akihito Kawazoe, Masako Asayama, Takako Yoshii, Daisuke Kotani, Hitomi Tamura, Yuichi Mikamoto, et al. Updated results from a phase Ib trial of regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer (REGONIVO, EPOC1603). JOURNAL OF CLINICAL ONCOLOGY. 2020. 38. 4
ｍore...
Return to Previous Page
